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Abstract 
OBJECTIVE: Our aims were to evaluate the similarity of the peptide repertoires bound 
to HLA-DR molecules that are differentially associated with rheumatoid arthritis and 
define structural features of the shared peptides. 
METHODS: Peptide pools bound to HLA-DRB1*01:01, HLA-DRB1*04:01, and HLA-
DRB1*10:01 (associated) and HLA-DRB1*15:01 (non-associated) were purified and 
analyzed by LC-MALDI and LC-ion-Trap mass spectrometry. The peptide pools from 
each allotype were compared in terms of size, protein origin, composition and affinity 
(theoretical and experimental with some peptides). Finally, one peptide sequenced from 
DR1, DR4 and DR10, but not from DR15 was modeled in complex with all four HLA-
DRB1 molecules and HLA-DRB5*01:01.  
RESULTS: A total of 6309 masses and 962 unique peptide sequences were compared. 
DR10 shared 29 peptides with DR1, 9 with DR4 and 1 with DR15; DR1 shared 6 
common peptides with DR4 and 9 with DR15; and DR4 and DR15 shared 4 peptides. 
The direct identification of peptide ligands indicated that DR1 and DR10 are the most 
similar molecules regarding the peptides that they can share. The common peptides 
between these molecules contain a high proportion of Leu at P4 and basic residues at P8 
binding core positions. 
CONCLUSION: The degree of overlap between the peptide repertoires associated to 
different HLA-DR molecules is low. The repertoires associated to DR1 and DR10 have 
the highest similarity among the molecules analyzed (around 10% overlap). Among the 
shared peptides between DR1 and DR10 a high proportion contained Leu4 and basic 
residues at P8 position of the binding core. 
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Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease affecting 
peripheral joints. The etiopathogenesis of the disease is complex involving both 
environmental and genetic factors. The strongest genetic association is with the human 
leukocyte antigen (HLA)-DRB1  locus (1-3), although other genes have also been 
related with RA, including PTPN22, IL23R, TRAF1, CTLA4, IRF5, STAT4, CCR6, 
PADI4 and others (1, 4). HLA-DR molecules bind peptides mostly generated during the 
catabolism of proteins located in the endocytic pathway and present them to CD4
+
 T 
lymphocytes. Some HLA-DR alleles are positively associated with the disease, 
including some subtypes of HLA-DR4 (DRB1*04:01, DRB1*04:04, DRB1*04:05, 
DRB1*04:08), HLA-DR1 (DRB1*01:01, DRB1*01:02) and HLA-DR10 (DRB1*10:01), 
while other alleles are negatively associated with seropositive RA, as HLA-DRB1*03:01, 
HLA-DRB1*07:01, HLA-DRB1*08:01 or are considered as non-associated or low-risk 
alleles, as HLA-DRB1*15:01 (2, 5). The RA-associated molecules have a consensus 
sequence spanning residues 70-74 of the HLA-DR β-chain containing basic residues. 
This feature led to the proposal of the “shared epitope” (SE) hypothesis (6), which 
postulates that this motif can modulate the T cell recognition, by either directly 
interacting with the T cell receptor (TCR) or defining the HLA-DR-associated peptide 
repertoire by direct interaction with the peptides. One of the molecular contacts between 
the HLA-DR molecule and the peptide is among the residue 71 of the DRβ chain and 
the P4 position of the peptide binding core (7-9). The presence of basic residues in this 
position impairs the binding of basic residues, such as Arg, at the peptide P4 core 
position. However, RA-associated HLA-DR molecules allow the presence of Gln, 
which is similar to citrulline, at the P4 anchor position. The presence in the serum of 
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RA patients of citrullinated protein-specific antibodies is closely linked to the 
expression of the SE alleles (10, 11).  
HLA-DR4 is associated to RA in many populations, principally in Northern Europe (12), 
while DR1 and DR10 are predominant in RA patients in some populations of Southern 
Europe (13-15) and others (16-18). The peptide anchor motif of HLA-DRB1*10:01 was 
described by our group by sequencing its peptide repertoire partially (19). The anchor 
motif was subsequently confirmed by other techniques with small differences (20). 
Theoretically, there should be a higher degree of overlap between the peptide 
repertoires bound by SE-containing HLA-DR allotypes, such as DRB1*01:01 and 
DRB1*04:01, than with the repertoires bound to other low-risk or negatively associated 
molecules, as DRB1*15:01 or DRB1*07:01 (19). Such repertoires could be inferred 
based on bioinformatics based prediction tools. However, the available tools use 
different algorithms and differ in their assignations of the theoretical affinity. Therefore, 
direct sequencing of the peptide ligands of HLA-DR molecules is required to identify 
peptides that are bound to them and to confirm theoretical data. The identification of 
natural ligands of different alleles in samples processed in parallel could reveal 
structural features that allow some peptides to bind to SE-containing alleles but not to 
other RA-non-related molecules. 
HLA-DR molecules are promiscuous regarding the peptides they can bind (21, 22). 
However, a direct quantification of the overlapping degree between different HLA-DR 
allotypes differentially associated to RA has not yet been performed. This approach has 
been successfully performed to compare the peptide pools sequenced from different 
HLA-B27 subtypes and to quantify the overlapping degree of these peptide repertoires 
(23-25). Here, we describe a comparison of the peptide repertoires bound to HLA-DR 
alleles differentially associated to RA. Our analysis included three of the most clearly 
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RA-associated alleles: HLA-DRB1*01:01, HLA-DRB1*04:01, HLA-DRB1*10:01, and a 
non-associated allele, HLA-DRB1*15:01. Homozygous lymphoblastoid cells (LCSs) 
were used as the source of the peptide-HLA-DR complexes (pHLA-DR), which were 
purified by immunoaffinity chromatography. After acid elution and ultrafiltration, 
peptides were analyzed by LC-MALDI AND LC-ion Trap mass spectrometry (MS). 
The analysis of the peptide pools indicated that the overlapping of the peptide 
repertoires of different HLA-DR molecules is relatively low. The two most similar 
HLA-DR peptide repertoires are those from DR1 and DR10 which shared a high 
proportion of peptides with Leu at the P4 binding core position and basic residues at P8. 
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Materials and methods 
Cell lines and antibody 
Homozygous EBV-transformed B-lymphoblastoid cell lines (B-LCL) from the 10th 
International Histocompatibility Workshop include HOM-2 
(DRA1*01:01/DRB1*01:01), MGAR (DRA1*01:01/DRB1*15:01) and WT51 
(DRA1*01:01/DRB1*04:01). The HLA-DR10 homozygous B-LCL BEN 
(DRA1*01:01/DRB1*10:01) was previously described (19). The sequence alignment of 
the DRB1 alleles is shown in the Supplementary figure 1. Cells were grown in roller 
bottles in RPMI (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine 
serum (Invitrogen, Carlsbad, CA). Cells were washed three times in cold phosphate 
buffered saline (PBS), and dry pellets stored at -70°C until processing. The HLA–DR–
specific monoclonal antibody B8.11.2 (IgG2b) (26) was used for pHLA-DR purification. 
 
HLA-DR-associated peptide pool purification 
Peptide-HLA–DR complexes were purified as described (19, 27). Procedures are 
detailed in Supporting information.  
 
LC-MALDI-TOF/TOF 
Peptides were fragmented by reverse phase high performance liquid chromatography 
(RP-HPLC). Fractions were taken every 15 seconds and analyzed in a matrix-assisted 
laser desorption/ionization-time of flight (MALDI-TOF) UltrafleXtreme (Bruker 
daltonics, Bremen, Germany).  
The peptide repertoires from the different allotypes were compared by pairs using the 
software MSHandler (28), setting the system as follows: the selected mass range was 
1100-3000 Da; tolerances used to judge two mass signals as equivalent peptide were set 
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as +/-0.25 Da/z for the m/z value and +/-2 elution positions for the chromatographic 
retention time; the signal intensity cut off for the whole spectrum was 100, in absolute 
value of intensity units, and the specific signal cut off, discarding signals likely assigned 
as specific in a mistaken way by lack of instrumental accurateness, was 500; the specific 
signals search width, discarding signals that are likely assigned as specific due to a shift 
between both chromatographic profiles, was +/-6 elution positions.  
A False Discovery Rate (FDR) for the search method, depicting the probability that two 
different chromatographies show two equivalent masses corresponding to different 
peptides, was specifically calculated for each comparative analysis performed. FDR 
calculation was carried out by determining the overlay between the real sample 
chromatography and a fictional chromatography so-called decoy. The decoy was made 
by calculating the mass of a wide pool of randomly generated amino acid sequences 
containing 9-27 residues which were distributed along 250 theoretical chromatographic 
fractions, placing 20-30 masses in each fraction. 
 
Ion Trap Mass Spectrometry and sequence identification  
Peptides were analyzed by a tridimensional ion trap mass spectrometer (Esquire HCT 
Ultra, Bruker, Bremen, Germany) (19, 29) and a high-resolution mass spectrometer, 
linear trap quadrupole (LTQ-Orbitrap XL, ThermoFisher, San Jose, CA) (29-31). 
Procedures are detailed in Supporting information.  
 
Predicted binding affinity 
The theoretical binding of each peptide to the different HLA-DR molecules was 
calculated using the NetMHCIIpan 3.1 Server. The IC50 value was considered. Peptides 
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with an IC50 lower than 50 nM were defined as strong binders (SB); between 50 and 
500 nM as intermediate binders (IB); and higher than 500 nM as weak binders (WB). 
 
Peptide HLA-DR binding assay 
The experimental affinity of some peptides to HLA-DR molecules was assayed as 
previously described (30). Briefly, recombinant DR1 (DRA1*01:01/DRB1*01:01), 
DR4 (DRA1*01:01/DRB1*04:01), DR10 (DRA1*01:01/DRB1*10:01), DR2b 
(DRA1*01:01/DRB1*15:01), DR2a (DRA1*01:01/DRB5*01:01) proteins were used 
for peptide binding assays. Increasing concentrations of each non-biotinylated test 
peptide were incubated in competition with 0.02 mM biotinylated haemagglutinin 
HA306-318 peptide in wells coated with HLA-DR1 or HLA-DR4 protein, 0.01 mM 
biotinylated TT560–571 peptide in wells coated with HLA-DR10 protein, and 0.01 mM 
biotinylated modified GAD555-567 peptide (NLIRVVSSNRAAT, modified from 
NFFRMVISNPAAT to bind to DR1501 and DRB5 in a single unambiguous register) in 
wells coated with HLA-DR2a and HLA-DR2b. After washing, residual biotinylated 
reference peptide was labeled using europium conjugated streptavidin (Perkin Elmer) 
and quantified using a Victor3 D time resolved fluorometer (Perkin Elmer). Peptide 
binding curves were simulated by non-linear regression with Prism software (Version 
4.03, GraphPad Software Inc.) using a sigmoidal dose-response curve. IC50 binding 
values were calculated from the resulting curves as the peptide concentration needed for 
50% inhibition of reference peptide binding. 
 
Modeling 
Modeling of complexes between HLA-DR1 (DRB1*01:01), HLA-DR4 (DRB1*04:01), 
HLA-DR10 (DRB1*10:01), HLA-DR2b (DRB1*15:01) or HLA-DR2a (DRB5*01:01) 
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and the peptide IVTERSVSS was performed using a simulation protocol introduced 
elsewhere (32) (see Supporting Information). This procedure delivers a binding score 
that can be used to (crudely) estimate the relative binding affinity of different peptides 
for the same HLA molecule. 
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Results 
Overlapping of the HLA-DR peptide repertoires 
The HLA-DR peptide pools that were eluted from DR1, DR4, DR10 and DR15 
respectively were purified and analyzed by two different techniques: LC-MALDI-
TOF/TOF and LC-ion trap MS. To evaluate the degree of overlap between the different 
peptide repertoires the peptide pools were fragmented by RP-HPLC and 240 fractions 
for each pool were collected and analyzed by MALDI-TOF/TOF. A total of 6309 
signals with m/z ranging from 1100 to 3000 were considered: 1594 from DR1, 1278 
from DR4, 1248 from DR10 and 2189 from DR15. The peptide repertoires were 
compared by pairs. The most similar pools were those from DR1 and DR10 which 
shared 10.4% and 9.4% of the masses analyzed, respectively (Table 1). These data 
confirmed the promiscuity of the peptides bound to HLA-DR molecules, but the 
overlapping of the repertoires was low.  
The low peptide overlapping degree could be due to differences in the peptide 
fractionation by RP-HPLC. To discard it, the most abundant masses of all fractions 
were fragmented by MALDI-TOF/TOF, obtaining a total of 73 peptide sequences: 11 
from DR1, 38 from DR4, 19 from DR10 and 5 from DR15. Some of the sequences 
corresponded to the same peptides shared by two HLA-DR molecules. These peptides 
had the same retention time in the HPLC chromatogram. The figure 1 shows two 
examples of peptides sequenced from DR1 and DR10 from equivalent HPLC fractions. 
These data confirmed that the low overlapping degree were not due to differences in the 
peptide fractionation.   
 
Size distribution and origin of the peptides bound to HLA-DR molecules 
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HLA-DR natural ligands were also sequenced by LC-ion Trap MS. A total of 962 
unique (non-redundant) HLA-DR ligands were identified: 229 from DR1, 285 from 
DR4, 270 from DR10 and 178 from DR15 (Supplementary table 1). The lengths of the 
peptides composing the four peptide pools were comparable. When we consider the 
masses obtained by LC-MALDI, all the peptide pools were similar, with an average m/z 
of 1594.6 for DR1, 1576.5 for DR4, 1616.5 for DR10 and 1645.2 for DR15 
(Supplementary figure 2). A similar result was obtained considering the peptide 
sequences. Thus, the average amino acid number was 15.3 for DR1, 15.4 for DR4, 15.3 
for DR10, and 15.6 for DR15 (Figure 2A).  
The cell location of the parental proteins was also analyzed. A protein was considered 
for each nested set. The peptide pool derived from 121 different proteins in DR1, 79 in 
DR4, 128 in DR10 and 69 in DR15. The protein location described in the Uniprot 
database (http://www.uniprot.org) and the Human Protein Reference Database 
(http://www.hprd.org/) was considered as previously used (29). When a protein was 
located in different cell compartments, the most usual was chosen. Most of the parental 
proteins of the HLA-DR ligands (ranging from 63.3% to 82.3%) were located in 
compartments of the endocytic pathway (membrane, secreted, vesicles, endoplasmic 
reticulum and Golgi apparatus) (Figure 2B). As previously observed for these and other 
MHC class II molecules (MHC-II), a percentage of the peptide ligands derived from 
cytosolic, nuclear or mitochondrial proteins, ranging from 16.5% to 33.6% (Figure 2B).  
 
Theoretical affinity of the HLA-DR ligandome 
The theoretical binding affinity of the peptides sequenced from each of the HLA-DR 
molecules to this and the other allotypes was determined by calculating the IC50 values 
using the NetMHCIIpan-3.1 Server (33). MGAR expresses the protein product encoded 
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in two loci (DRB1 and DRB5) and the alleles are known (DRB1*15:01, also called 
DR2b and DRB5*01:01 or DR2a). Thus, DR2a was included in the analysis. The 
peptide pool associated to DR1 contained less weak binders to itself (7.86%) and to 
DR10 (21.83%) than to the other HLA-DR molecules (Supplementary table 2). The 
same was seen for the DR10 peptide pool which contained less weak binders to itself 
(28.89%) and to DR1 (16.30%) than to the other allotypes (Supplementary table 2). 
Therefore, the peptides bound to DR1 seem to have more capacity to bind to DR10 than 
to the other molecules, and the same occurs for the peptides bound to DR10 regarding 
DR1. This data are in accordance with the results observed by the LC-MALDI-TOF 
analysis (Table 1). All the peptide pools have a lower number of theoretically weak 
binders for DR1 than for the other molecules. However, the peptides sequenced from 
DR1 have a higher preference to bind to DR10 than to DR4, DR2b or DR2a. 
 
Identification of common peptides between HLA-DR alleles 
To directly evaluate the degree of overlap between the peptide repertoires, we analyzed 
the common peptides bound to the different HLA-DR molecules. When we studied the 
peptides shared between HLA-DR10 and any other HLA-DR molecule we observed 
that 26 peptides were common to DR10 and DR1; 6 peptides were common to DR10 
and DR4; but none were shared between DR10 and DR15.  HLA-DR1 shared 1 peptide 
with DR4 and 6 with DR15. DR4 shared 1 peptide with DR15. In addition, 2 peptides 
were mutually shared by DR10, DR1 and DR4 and 2 peptides were mutually shared by 
DR1, DR4 and DR15. Finally, one peptide was common to all four allotypes (Table 2). 
Therefore, DR10 shared a total of 29 peptides with DR1 (10.7% and 12.4% of the 
sequenced peptides, respectively), 9 with DR4 (3.3% and 3.2%) and 1 with DR15 (0.4% 
and 0.6%). HLA-DR1 presented 6 common peptides with DR4 (2.6% and 2.1%) and 9 
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with DR15 (3.9% and 5.1%). Finally, DR4 and DR15 shared a total of 4 peptides (1.4% 
and 2.2%).  
Some of these common peptides are part of a nested set of peptides. If we consider each 
peptide family as one unique peptide sequence, then 25 peptides were shared between 
the different HLA-DR molecules: 1 peptide was common to the 4 alleles; 1 peptide to 
DR1, DR4 and DR10; 18 peptides to DR1 and DR10; 2 peptides to DR10 and DR4; 2 
peptides to DR1 and DR15; and 1 peptide to DR4 and DR15. Therefore, these data 
clearly confirm that the peptide repertoire associated to HLA-DR1 is the most similar to 
that bound to DR10. 
 
Features of the common peptides between HLA-DR molecules 
To evaluate similar features of the common peptides we considered the only peptide set 
with a number of components high enough: the peptides shared between DR10 and DR1. 
As said above, 18 of the 25 shared nested sets were common to DR1 and DR10. There 
was a clear bias to Leu at the P4 position of the anchor core among these peptides 
(Table 3). Fourteen of the 18 common peptides (77.8%) contained Leu4, while only 2 of 
the 7 remaining shared peptides (28.6%) comprised Leu4. These peptides contained Ala, 
Glu, Asp and Leu (Table 3). The peptide SPNIVIALAGNKAD presented 
VIALAGNKA as the theoretical core for DR1, DR4, DR10 and DR2b, while 
IVIALAGNK was the theoretical core for DR2a. About 35% of the ligands eluted from 
DR1 and 38% from DR10 contained Leu4. However, only 4% and 18% of the DR4 and 
DR15 ligands presented Leu4. Thus, although the presence of Leu4 is accepted in all 
allotypes, it is clearly favored in DR1 and DR10. On the other hand, most of the 
common peptides that included DR4 as one of the molecules from which they were 
eluted contained an acidic amino acid in the P4 core position. About 29% of the 
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peptides eluted from DR4 had Asp or Glu at P4, in comparison with the 22% from DR1, 
15% from DR10 and 12% from DR15.  
Peptides shared by DR1 and DR10 had a preference for basic residues at the P8 core 
position. Thus, 61.2% of the common peptides had a basic residue at this position (27.8% 
Arg, 27.8% Lys and 5.6% His). None of the peptides shared with other molecules had 
basic residues at this position. However, all the molecules accepted basic residues at P8 
(DR1: 33.6%, DR4: 19.8%, DR10: 31.0% and DR15: 24.0%). 
 
Binding assay of shared peptides to HLA-DR molecules 
The peptides VTQEIVTERSVSSRQA, SPSIVIALAGNKADL, DHNFVKAINAIQKS 
and APSTYAHLSPAKTPPP were synthesized and their binding affinity to 
DRB1*01:01, DRB1*04:01, DRB1*10:01, DRB1*15:01 and DRB5*01:01 was 
experimentally calculated with a binding assay. These peptides were differentially 
found in the repertoires of these allotypes: VTQEIVTERSVSSRQA was sequenced 
from DR1, DR4 and DR10; APSTYAHLSPAKTPPP from DR1 and DR10; 
SPSIVIALAGNKADL from DR1 and DR15; and DHNFVKAINAIQKS from DR4 and 
DR15. All the peptides had high affinity for the HLA-DR molecule from which they 
were identified (Table 4). In addition, the peptides had low affinity to the alleles from 
which they were not sequenced. A few peptides not detected in a specific peptide 
repertoire can bind to the corresponding molecule with a reasonably good affinity. Thus, 
the peptide VTQEIVTERSVSSRQA was observed to bind to DRB1*15:01 with a high 
affinity (IC50 = 0.55 nM); the peptide DHNFVKAINAIQKS to DRB1*10:01 with a 
IC50 = 1.75 nM, although this was 25 times lower than to the molecules where it was 
identified (0.04 nM to DRB1*04:01 and <0.05 nM to DRB1*15:01 or 0.07 nM to 
DRB5*01:01); and the peptide APSTYAHLSPAKTPPP to DRB5*01:01, to which the 
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affinity was also much lower than to the alleles from which the peptide was sequenced 
(18.15 nM to DRB5*01:01 vs. 0.15 nM to DRB1*01:01 and 0.09 nM to DRB1*10:01). 
Therefore, the experimental binding results were highly consistent with the data of 
peptide sequencing and the source from which they were sequenced. 
 
Modeling of the peptide-MHC interaction 
The peptide with sequence VTQEIVTERSVSSRQA, derived from desmoglein-2, was 
found to be bound to the three HLA-DR molecules associated to RA but not to DR15. 
The binding assays confirmed the high affinity of this peptide for DR1, DR4 and DR10 
and indicated that it could also bind to DR2b but not to DR2a (Table 4). The interaction 
of the peptide core (IVTERSVSS) with the four HLA-DRB1 molecules and HLA-
DRB5*01:01 was studied by computational modeling. The results are compatible with 
the binding data, predicting a lowest binding affinity of the peptide for DR2a. The 
models and computed relative binding scores are shown in supplementary figure 3. 
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Discussion 
Here, we present a comparison of the HLA-DR peptide repertoires of three of the most 
strongly RA-associated HLA-DR allotypes containing the SE (DRB1*01:01, 
DRB1*04:01 and DRB1*10:01) and a non-associated HLA-DR molecule (DRB1*15:01) 
in order to analyze the overlapping degree of these repertoires and deduce structural 
features of the peptides shared by these allotypes. Different studies have analyzed the 
peptide pools of several of these HLA-DR molecules (19, 21, 34-36), but not as a 
comparative study. The identification of structural features of the peptides bound to 
differentially RA-associated alleles is required to define putative target of the T cell 
immune response presented by RA-related molecules. These peptides would have the 
potential to be used for the development of cell therapies (as the generation of 
tolerogenic dendritic cells, development of peptide vaccines, etc.). 
The promiscuity of the MHC-II molecules to bind identical peptides was demonstrated 
long-time ago (21, 22). In the case of RA, two of the SE molecules, DR1 and DR4, bind 
an immunodominant type II collagen peptide that interacts with the same residues of 
both molecules (37). However, the overlapping degree of the peptide repertoires bound 
to HLA-DR alleles differentially associated to RA has not yet been measured. For that, 
we have analyzed the peptide pools bound to these four HLA-DR molecules. First, we 
compared by LC-MALDI-TOF/TOF 240 fractions of each peptide pool. Although the 
peptide repertoires contained common peptides, the global overlap between the peptide 
pools bound to two HLA-DR was low, around 10% in the two more similar repertoires 
(DR1 and DR10). Analysis of the peptides sequenced by mass spectrometry clearly 
confirmed this low overlapping degree and that DR1 and DR10 had the most similar 
peptide repertoires, sharing 12.7% and 10.7% of the peptides, respectively. The 
percentage of common peptides by any other pair of molecules did not exceed 5.1%. 
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The overlap of the peptide pools described previously for several HLA-B27 subtypes 
using similar technology was much higher (23, 24). Several subtypes of HLA-DR4 are 
clearly associated to RA (DRB1*04:01, DRB1*04:04, DRB1*04:05, DRB1*04:08), 
while others can be considered as low risk alleles (DRB1*04:02) or non-associated 
alleles (DRB1*04:03, DRB1*04:07) (5). The anchor motifs of HLA-DRB1*04:01, 
HLA-DRB1*04:02 and HLA-DRB1*04:04 have been identified based on peptide 
ligands (36), although the overlapping of the repertoires was not described.  
One peptide derived from desmoglein-2, VTQEIVTERSVSSRQA, was sequenced from 
DR1, DR4 and DR10 peptide pools. The peptide core-MHC modeling of the putative 
cores correlated very well with the empiric binding data. Thus, this peptide binds with 
high affinity to DR1, DR4, DR10 and DR2b, but not to DR2a. In the literature, some 
promiscuous peptides have been analyzed, but DR10 had not been yet included as one 
of the HLA-DR alleles. This peptide contains Glu4 as one of the anchor residues.  
Other peptide, LPSYEEALSLPSKTPE, derived from Lysosomal-associated 
transmembrane protein 5, was sequenced from all the allotypes analyzed. Although this 
self-peptide would not have any immune implications, is in our knowledge the first 
natural ligand sequenced from four differently RA-associated HLA-DR molecules with 
the exception of CLIP. This finding confirmed the existence of peptides very 
promiscuous regarding to the HLA-DR molecules they can bind to. However, the fact 
that only one peptide was found indicates that the number of peptides with the capacity 
to bind to many HLA-DR alleles is limited.  
Regarding the theoretical affinity data, DR1 was the allele to which more peptides could 
bind with high affinity. These data suggest that the NetMHCIIpan3.1 software 
overestimate the binding affinity with DR1 in comparison with other allotypes. This 
was confirmed with the data of the binding affinity. Although the theoretical data 
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correlated well with most of the peptides and alleles, some discrepancies were detected. 
In all cases, the peptides were good binders for DR1, included the peptide 
DHNFVKAINAIQKS, which was not detected as a DR1 ligand and was not bound to 
DR1 in the binding assay.  
The identification of the binding core was made using the NetMHCIIpan 3.1 software. 
The only way to be conclusive in the identification of the peptide binding core is with 
structural analysis. However, although we do not discard that a few cores assigned can 
be wrong, this number should be very low and should not affect to the global analysis.  
Only the number of peptides shared between DR1 and DR10 allowed the search of 
some structural features of the common peptides. Two features were observed: most of 
the peptides had Leu in P4 and basic residues in P8. These residues were enriched when 
compared with their presence in the individual peptide repertoires, as the abundance of 
Leu4 and basic residues at P8 in the shared peptides is around the double than in DR1 or 
DR10 alone. Therefore, although a higher number of peptides is required, these data 
suggest that the peptides containing Leu4 and basic residues at P8 are favored to bind to 
DR1 and DR10 and not to other molecules. One exception is the peptide 
SPSIVIALAGNKADL which was found in the peptide repertoires of DR1 and DR15. 
The binding assay demonstrated that this peptide was a good binder for DR1 and DR2a, 
but not to DR4, DR10 and DR2b. The core for DR2a was IVIALAGNK, lacking the 
Leu4 and Lys8. 
The polar residues Ser and Asn are the most abundant residues in the P9 core position 
of DR10 (19% and 20% of the peptide families, respectively). Ser was also detected in 
the other peptide pools (11% in DR1, 21% in DR4 and 10% in DR15). However, Asn 
was not detected in any of the DR1 and DR15 ligands, and only 2% of the peptides 
bound to DR4 had Asn9. Thus, although the P9 core position accepted a high number of 
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different residues, mostly polar and small aliphatic residues, only DR10 have Asn as a 
favoured residue. Therefore, our data strongly suggest that peptides shared by DR1 and 
DR10 are enriched in Leu4, basic residues at P8 and do not contain Asn at P9.  
About 60% of RA patients contain antibodies anti-citrullinated proteins (38) what 
highly correlates with the expression of the SE allotypes (39). The identification of 
citrullinated peptides directly from the eluted peptide pool is very difficult (40) 
Glutamine is an amino acid with similar physicochemical features to citrulline. The 
presence of Gln4 may be an indirect clue of the acceptance of citrulline at the P4 core 
position. The four peptide repertoires contained peptides with Gln4 (DR1: 6.4%, DR4: 
14.3%, DR10: 6.7 and DR15: 5.6%). Thus, the analysis of these peptide pools suggests 
that DR4 may be the allele with the higher probability to present peptides containing 
citrulline in the P4 core position. The binding of peptides with this modification to DR4 
have been described (41). DR15 had the lower amount of peptides with Gln4, but with a 
percentage very similar to DR1 and DR10. 
The characterization of peptide sequence patterns between common peptides bound to 
RA-associated molecules and absent in RA-non-associated allotypes may be used to 
identify new joint autoantigen-derived T cell epitopes differentially presented in the 
patients. 
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Figure legends 
Figure 1. Two examples of the comparison of the DR1-, DR4-, DR10- and DR15-
bound peptides bound by LC-MALDI-TOF/TOF MS. A) Fraction N. G16 was 
compared between the different allotypes. The peak with the mass 1721.9 
corresponded to the peptide RVEYHFLSPYVSPK, as sequenced by MALDI-TOF/TOF. 
This peptide eluted in the same fraction from DR1 and DR10 but was not detected in 
DR4 and DR15 in the fractions G14 to G18. The closest masses, 1730.9 and 1726.9, are 
labeled in DR4 and DR15, respectively. B) Fraction N. J16 was compared between 
the different allotypes. The peak with the mass 1436.8 corresponded to the peptide 
QQYLPLPTPKVIG, as sequenced by MALDI-TOF/TOF. This peptide eluted in the 
same fraction from DR1 and DR10 but was not detected in DR4 and DR15 in the 
fractions J14 to J18. The closest masses, 1446.7 and 1391.8, are labeled in DR4 and 
DR15, respectively. 
 
Figure 2. A. Peptide size distribution of the peptides sequenced from the different 
HLA-DR allotypes. Values shown are the percentage of peptides with a specific amino 
acid number. B. Major cell location of the parental proteins of the peptides 
sequenced from the different HLA-DR molecules. Values shown are the percentage 
of proteins for each intracellular location. M, membrane; C, cytosol; V, vesicular 
compartments; S, secreted; G, Golgi apparatus; ER, endoplasmic reticulum; N, nucleus; 
Mit, mitochondria; ND, not determined. The inner circle indicated the percentage of 
parental proteins with a major location in the endocytic pathway (dark grey), the 
endogenous pathway (light grey) and not determined (black).  
.
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Table 1. Percentage of common molecular masses between the different haplotypes 
detected by LC-MALDI-TOF. 
 
 LEFT ALLELE  (%) RIGHT  ALLELE (%) 
DR1 vs. DR4 4.35 3.88 
DR1 vs. DR10 10.40 9.36 
DR1 vs. DR15 6.66 3.49 
DR4 vs. DR10 6.47 6.57 
DR4 vs. DR15 9.00 5.30 
DR10 vs. DR15 8.41 4.85 
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Table 2. Common peptides associated to different HLA-DR molecules. 
PEPTIDE SEQUENCE PROTEIN HOM-2 BEN WT51 MGAR 
   (DR1) (DR10) (DR4) (DR15) 
LPSYEEALSLPSKTPE 
Lysosomal‐associated 
transmembrane protein 5 X X X X 
VTQEIVTERSVSSRQA Desmoglein‐2 X X X   
VVLPSYEEALSLPSKTPE 
Lysosomal‐associated 
transmembrane protein 5 X X X   
LPSYEEALSLPSKTP 
Lysosomal‐associated 
transmembrane protein 5 X   X X 
LPSYEEALSLPSKTPEG 
Lysosomal‐associated 
transmembrane protein 5 X   X X 
AEPNYHSLPSARTDEQ 
Ragulator complex protein 
LAMTOR1 X X     
APSTYAHLSPAKTPPP 
Lipolysis‐stimulated lipoprotein 
receptor X X     
APSTYAHLSPAKTPPPP 
Lipolysis‐stimulated lipoprotein 
receptor X X     
APSTYAHLSPAKTPPPPA 
Lipolysis‐stimulated lipoprotein 
receptor X X     
ASAFAFLAPARAIL 
Solute carrier family 23 member 
2 X X     
DARSYTAAVANRAKGGG Myotubularin‐related protein 4 X X     
DFYKILGVPRSASIK 
DnaJ homolog subfamily B 
member 11 X X     
Scholz et al. RA 25 
IEKFEKEAAEMGKG Elongation factor 1‐alpha 1 X X     
ISQELEELRAEQQRL 
Low affinity immunoglobulin 
epsilon Fc receptor X X     
KGRLDYLSSLKVKGLV 
4F2 cell‐surface antigen heavy 
chain X X     
LPTSFGSLAPAPLVFPGP 
E3 ubiquitin‐protein ligase 
RNF167 X X     
LPVILDIIKGEMSRPG Proactivator polypeptide X X     
NPKTFFILHDINSDG Nucleobindin‐1 X X     
QQYLPLPTPKVIG Heat shock 70 kDa protein 13 X X     
QQYLPLPTPKVIGID Heat shock 70 kDa protein 13 X X     
QYLPLPTPKVIGID Heat shock 70 kDa protein 13 X X     
RVEYHFLSPYVSP Transferrin receptor protein 1 X X     
RVEYHFLSPYVSPK Transferrin receptor protein 1 X X     
RVEYHFLSPYVSPKE Transferrin receptor protein 1 X X     
SPEDEYELLMPHRIS 
Germinal center‐associated 
signaling and motility protein X X     
SPEDEYELLMPHRISS 
Germinal center‐associated 
signaling and motility protein X X     
SPERPFLAILGGAKVADK Phosphoglycerate kinase 1 X X     
SPTNYHFLSSPKEA Beta‐mannosidase X X     
TPDPSKFFSQLSSEHGGD 
Interleukin‐2 receptor subunit 
beta X X     
TPDPSKFFSQLSSEHGGDV 
Interleukin‐2 receptor subunit 
beta X X     
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VDKVIQAQTAFSANPA Syntenin‐1 X X     
DDTQFVRFDSDAASPR 
HLA class I histocompatibility 
antigen, B‐14 alpha chain 
 
X X 
 
VDDTQFVRFDSDAASPR 
HLA class I histocompatibility 
antigen, B‐14 alpha chain   X X   
GNYRIESVLSSSG Ganglioside GM2 activator   X X   
TGNYRIESVLSSSG Ganglioside GM2 activator   X X   
TGNYRIESVLSSSGK Ganglioside GM2 activator   X X   
TTGNYRIESVLSSSGK Ganglioside GM2 activator   X X   
VTQEIVTERSVSSRQAQ Desmoglein‐2 X   X   
EDPAFYMLKGKLQYE Interleukin‐21 receptor X     X 
PAFYMLKGKLQYE Interleukin‐21 receptor X     X 
SPNIVIALAGNKAD Ras‐related protein Rab‐5C X     X 
SPNIVIALAGNKADL Ras‐related protein Rab‐5C X     X 
SPSIVIALAGNKAD Ras‐related protein Rab‐5B X     X 
SPSIVIALAGNKADL Ras‐related protein Rab‐5B X     X 
DHNFVKAINAIQKS Dipeptidyl peptidase 1     X X 
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Table 3. Theoretical cores of the common peptides associated to HLA-DR 
molecules and P4 residues used by them. 
PEPTIDE BINDING CORE* 
HOM-2 
(DR1) 
BEN 
(DR10) 
WT51 
(DR4) 
MGAR 
(DR15) 
P
4 
YEEALSLPS X X X X A 
IVTERSVSS X X X  E 
YHSLPSART X X   L 
YAHLSPAKT X X   L 
FAFLAPARA X X   L 
YTAAVANRA X X   A 
YKILGVPRS X X   L 
FEKEAAEMG X X   E 
LEELRAEQQ X X   L 
LDYLSSLKV X X   L 
FGSLAPAPL X X   L 
LDIIKGEMS X X   I 
FFILHDINS X X   L 
YLPLPTPKV X X   L 
YHFLSPYVS X X   L 
YELLMPHRI X X   L 
LAILGGAKV or FLAILGGAK1 X X   
L 
or 
I 
YHFLSSPKE X X   L 
FSQLSSEHG X X   L 
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IQAQTAFSA X X   Q 
VRFDSDAAS  X X  D 
YRIESVLSS  X X  E 
FYMLKGKLQ X   X L 
VIALAGNKA or IVIALAGNK2 X   X 
L 
or 
A 
FVKAINAIQ or VKAINAIQK3   X X 
A 
or 
I 
 
*
Cores were selected using the NetMHCIIpan 3.1 Server. 
1
 FLAILGGAK to DRB1*10:01. 
2
 IVIALAGNK to DRB5*01:01. 
3
 VKAINAIQK to DRB5*01:01. 
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Table 4. Experimental binding affinity of shared peptides associated to HLA-DR 
molecules. 
PEPTIDE 
BOUND TO 
PEPTIDE 
SEQUENCE 
DRB1* 
01:01 
DRB1* 
04:01 
DRB1* 
10:01 
DRB1* 
15:01 
DRB5* 
01:01 
DR1-DR4-DR10 VTQEIVTERSVSSRQA 8.26 0.33 3.36 0.55 >50 
DR1-DR10 APSTYAHLSPAKTPPP 0.15 >50 0.09 >50 18.15 
DR1-DR15 SPSIVIALAGNKADL* 0.19 >50 >50 >50 <0.05 
DR4-DR15 DHNFVKAINAIQKS >50 0.04 1.75 <0.05 0.07 
- CONTROLS 0.07 0.16 0.93 0.05 0.1 
 
The theoretical binding core is highlited in bold. 
*The theoretical core for DRB5*01:01 is IVIALAGNK as defined by NetMHCII-
pan3.1. 
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